about
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerExploring the transcription factor activity in high-throughput gene expression data using RLQ analysisAnalysis with respect to instrumental variables for the exploration of microarray data structures.Stability of gene contributions and identification of outliers in multivariate analysis of microarray dataOutcome of treated advanced non-small cell lung cancer with and without central airway obstruction.Variable radiomorphologic data of high altitude pulmonary edema. Features from 60 patients.Therapeutic bronchoscopy for malignant airway stenoses: choice of modality and survival.Complementary and alternative medicine for bronchial asthma: is there new evidence?Prevalence of coeliac disease in patients with sarcoidosis.Oxygen kinetics during 6-minute walk tests in patients with cardiovascular and pulmonary disease.Accuracy of the Hospital Anxiety and Depression Scale for identifying depression in chronic obstructive pulmonary disease patients.Cytokine gene polymorphisms and atopic disease in two European cohorts. (ECRHS-Basel and SAPALDIA).Treatment of complicated spontaneous pneumothorax by simple talc pleurodesis under thoracoscopy and local anaesthesiaIn-Hospital Disease Burden of Sarcoidosis in Switzerland from 2002 to 2012.Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.Modeling the oxygen uptake kinetics during exercise testing of patients with chronic obstructive pulmonary diseases using nonlinear mixed models.Sarcoidosis is a multisystem disorder with variable prognosis--information for treating physicians.Impact of laughter on air trapping in severe chronic obstructive lung disease.Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details.24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.Interstitial pneumonitis after treatment with pemetrexed: a rare event?Functional genomics in sarcoidosis--reduced or increased apoptosis?Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.Transcutaneous versus blood carbon dioxide monitoring during acute noninvasive ventilation in the emergency department - a retrospective analysis.Therapeutic bronchoscopy interventions before surgical resection of lung cancer.Telehealthcare for Chronic Obstructive Pulmonary Disease in Switzerland Is Feasible and Appreciated by Patients.Longitudinal change of prebronchodilator spirometric obstruction and health outcomes: results from the SAPALDIA cohort.Determinants of annual change in physical activity in COPD.High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA).Induction chemotherapy followed by parenchyma-sparing surgery in medically inoperable NSCLC-results of a feasibility study.Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).End-stage cystic fibrosis: improved diabetes control 2 years after successful isolated pancreatic cell and double-lung transplantation.The outcome of community-acquired pneumonia in patients with chronic lung disease: a case-control study.Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing.Operator experience and long term outcome after percutaneous coronary intervention.VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.Hemodynamic effects of endobronchial application of ornipressin versus terlipressin.Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
P50
Q27852543-D95C2533-DE89-4DCF-B170-CA461C75F9F7Q30641977-E0D73869-0F65-41CE-ABB9-0B0D132EF73BQ31063139-6881D63C-14D2-49FE-9F4A-2B6C48C30703Q31159996-C65FD795-BF75-491A-9FEB-4D843159D941Q33266503-809433B2-DE55-4679-AFB7-8E004A2AB8BBQ33427926-71A5DAF8-0CCC-4BC9-908E-5C88F08CE5F3Q33630306-578BF250-4138-4790-9CF7-FCD04AA54560Q34293411-812E55B1-A6E2-493B-9B9D-17216BAF82FDQ34341864-1A05281C-6E5F-43D2-A87B-05C301B71E38Q34469646-983EF029-6656-4EFA-8582-7DE32F43356BQ34762551-9E92B821-5308-4256-BFEF-4C127B4A9F7EQ34973466-FD356118-BCF1-450A-93A1-81BA867AF875Q35563498-1E0BFB2C-AEDC-4895-A43D-F3C7D3221F5CQ35961291-46FFDA70-DC0D-4036-A974-1093BBC18265Q36027021-A2ACD8E8-813B-42F8-A81C-D99B5562E15BQ36035135-460EEF13-8692-4452-8154-61B8877F5FE8Q36457956-63AA718D-4075-46D9-A27D-85573BB91314Q36859434-02FB947F-349A-479E-8E36-9D109C53A5A3Q37578975-F96574EC-C3B9-4F1C-8324-3F9834912DA8Q37637169-3AD497FE-4B87-46A6-96A3-6F7BAE52E9E0Q37728603-BFF1A772-165D-42C6-88A8-704A0B6393C6Q37989303-D664B251-1D1E-4A60-98C2-12CEB81905EFQ38295572-D48F99E4-BF2E-4B67-81D0-20C4569455DCQ39021558-4F2205EC-89B5-43B7-B361-62607E530344Q39160161-666EF9A6-AABE-4425-A457-6134D8212742Q39352265-ABE82BD0-07FC-4F46-A2A8-22639AE8EF2EQ39461309-114C067D-5D13-402F-B206-B0951221410FQ39921070-E79441AE-97F5-43D4-9791-2732C195F322Q40261052-34A47F9C-9076-4490-A34B-8E91B5EA1477Q40413469-91B2D75B-9BCC-4A0C-B548-1937E69996E8Q40420711-093FAB1A-3638-4D7E-A9BC-E291B8D48A57Q41001434-8DD66392-05BA-4D86-B005-59DBD729F457Q41665631-B7173D11-9F54-4AE7-9304-4E3D8471F2F2Q41756503-24B0AB64-1C8E-4A27-867B-1AF698AF8028Q43519006-DDFE6784-A3E7-4DC3-A090-6E3435B107B1Q44513555-B31A78C8-2DD2-4098-8731-3678DDA262F7Q44658753-61C6C1DE-2904-4D19-B316-216BAB85933AQ44788451-D90ADC10-B325-49B6-8167-A7304801F18FQ45021906-BE7E8B4D-03DD-43C8-8207-BE5D7D82374BQ45181282-5F6251BE-9DE7-417C-B1FF-4B070C04950B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin H Brutsche
@ast
Martin H Brutsche
@en
Martin H Brutsche
@es
Martin H Brutsche
@nl
type
label
Martin H Brutsche
@ast
Martin H Brutsche
@en
Martin H Brutsche
@es
Martin H Brutsche
@nl
altLabel
Martin Brutsche
@en
prefLabel
Martin H Brutsche
@ast
Martin H Brutsche
@en
Martin H Brutsche
@es
Martin H Brutsche
@nl
P106
P31
P496
0000-0002-1612-3609